t
Roquefort Therapeutics plc announced on 1 December 2025 that its ordinary shares would be marked ex-entitlement for Unlisted Redeemable Non-Voting Shares, effective from the commencement of trading on that date. Eligibility for these Unlisted RNV Shares is for holders of ordinary shares and convertible loan notes on the Company's register at close of business on 28 November 2025, including those who purchased ordinary shares on Friday, 28 November 2025. A further announcement will detail the timetable, entitlement ratio, and exact number of shares.
| Date | 1 Dec 2025 |
| Time | 10:35:41 |
| Category | Corporate updates |
| ID | 6886J |
1 December 2025
Roquefort Therapeutics plc
("Roquefort Therapeutics" or the "Company")
Ex-Entitlement Date - Unlisted Redeemable Non-Voting Shares
Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company, announces that further to the Company's announcement earlier today confirming that the record date for determining entitlement to the Unlisted Redeemable Non-Voting Shares ("Unlisted RNV Shares") has now passed, its ordinary shares will be marked ex-entitlement in respect of the Unlisted RNV Shares with effect from the commencement of trading today, 1 December 2025.
Accordingly, all holders of ordinary shares and convertible loan notes who were on the Company's register as at close of business on 28 November 2025 will be eligible to receive the Unlisted RNV Shares. In addition, anyone who purchased ordinary shares on Friday, 28 November 2025 will also be eligible to receive the Unlisted RNV Shares.
A detailed timetable for the crediting of the Unlisted RNV Shares to eligible shareholders, together with full details of the entitlement ratio and the exact number of Unlisted RNV Shares to be issued, will be set out in a further announcement to be made in due course.
Regulatory Information
This Announcement contains inside information for the purposes of the UK version of the market abuse regulation (EU No. 596/2014) as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018 ("UK MAR").
ENDS
|
Roquefort Therapeutics plc |
+44 (0)20 3918 8633 |
|
Stephen West (Chairman) / Dr Darrin Disley (Interim MD) |
|
|
SP Angel Corporate Finance LLP (Broker to the Company) David Hignell / Vadim Alexandre / Devik Mehta |
+44 (0)20 3470 0470
|
|
Shard Capital Partners LLP (Broker to the Company) Damon Heath |
+44 (0)20 4530 6926
|
|
Burson Buchanan (Public Relations) Ben Romney / Jamie Hooper |
+44 (0)20 7466 5000
|
LEI: 254900P4SISIWOR9RH34
About Roquefort Therapeutics
Roquefort Therapeutics (LSE:ROQ) is focused on completing the proposed transaction with A2A Pharmaceuticals, Inc. and Coiled Therapeutics, Inc. which will result in the Company acquiring the exclusive licence rights to AO-252, a novel first-in-class, first-in-human new drug alternative targeting the TACC3 protein for the treatment of certain cancers, initially announced by the Company on 8 September 2025.
For further information on Roquefort Therapeutics, please visit www.roquefortplc.com